Lurasidone Hydrochloride Tablet, Film Coated
Product Images NDC 70518-4241

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lurasidone Hydrochloride (NDC 70518-4241). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Lurasidone hydrochloride 20 mg oral film-coated tablets, packaged quantity of 30 tablets. The label includes the NDC number 70518-4241-00, repackaged by RemedyRepack Inc., Indiana, PA. Manufacturer information indicates Dr. Reddy's, Shreveport, LA. Storage instructions specify 20-25°C with permitted excursions. Barcode and QR code are also present.*

FDA Label Image

Figure1 (Figure1)

A scatter plot chart showing the impact of various interacting drugs on the pharmacokinetics of Lurasidone, specifically changes in Cmax and AUC relative to lurasidone alone. The chart categorizes drugs as strong CYP3A4 inhibitors, moderate CYP3A4 inhibitors, and strong CYP3A4 inducers, with fold change values and 90% confidence intervals plotted along a horizontal axis from -4 to 4.*

FDA Label Image

Figure2 (Figure2)

A chart illustrating pharmacokinetic (PK) fold change and 90% confidence intervals for various interacting drugs relative to the interactive drug alone. It includes data for Digoxin 0.25 mg, Midazolam 5 mg, oral contraceptives Ethinyl Estradiol and Norelgestromin, and Lithium 600 mg BID, showing Cmax, AUC, and Ctrough measurements with horizontal error bars representing confidence intervals.*

FDA Label Image

Figure3 (Figure3)

A forest plot chart depicting fold changes and 90% confidence intervals for pharmacokinetic parameters Cmax and AUC relative to a reference. Data categories include renal impairment (mild, moderate, severe), hepatic impairment (mild, moderate, severe), and population descriptions by gender and race (females and Asians). Change relative to reference is shown on the x-axis.*

FDA Label Image

Structure (Structure)

Chemical structure of Lurasidone hydrochloride showing the molecular arrangement of its atoms, including multiple ring systems and heteroatoms, associated with the hydrochloride salt form.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.